AngioDynamics (ANGO) Tops Q2 EPS by 2c; Boosts Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AngioDynamics (ANGO) PT Raised to $21 at Piper Jaffray Amid Strong Q2
January 9, 2015 7:55 AM ESTPiper Jaffray analyst Thomas Gunderson reiterated an Overweight rating and boosted estimate and his price target on AngioDynamics (NASDAQ: ANGO) to $21.00 (from $17.00) following strong Q2 numbers.
Gunderson commented, "ANGO delivered a strong Q2 (Nov) relative to expectations with revenues of $92.1M (up 5%) and... More
